Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TERN vs ANL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TERN Captures Overall Composite Edge (51.9 HOLD vs 48.3 HOLD), While ANL Leads 3–2 on Growth & Valuation Pillars

TERN Overall Winner 6-Pillar Tally: TERN 2 – 3 ANL (1 Tie) Matrix Metrics: TERN 7 – 1 ANL

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (51.9/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. TERN trades at $52.95 (N/M Forward P/E, 0.0% operating margin) versus ANL at $9.97 (N/M Forward P/E, -123.5% operating margin).

  • Growth vs. Quality Trade-Off: TERN earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. ANL 48.3/100 HOLD) and 0.07β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TERN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 74.7); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TERN vs ANL
TERN NASDAQ Head-to-Head Winner
Terns Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$52.95
+0.04% 1D
Market Cap $6.1B
TTM Revenue $1.0M
Forward P/E N/M
Beta / 30D Vol 0.07β · 2% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 40.0 Fund 42.0 Flow 60.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 75
RSI-14: 74.7 · SMA20: $52.78 · SMA50: $49.21
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92

6-Pillar Scorecard Institutional Category Breakdown (TERN 2 – 3 ANL)

Columns: Metric · TERN · ANL
1. Valuation Multiples ANL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 37.5x
2. Growth & Scale ANL
Revenue Growth (YoY) +0.0% +178.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.0M $18M
Market Cap $6.1B $677.5M
3. Profitability & Quality TERN
Gross Margin 100.0% 100.0%
Operating Margin 0.0% -123.5%
Net Profit Margin 0.0% -124.8%
Return on Equity (ROE) -14.2% -20.2%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$110M EBITDA -$22M EBITDA
Cash Flow Margin N/A -119.9% EBITDA Mgn
Net Cash / Leverage $8.96 Book/Sh · -14.2% ROE $3.34 Book/Sh · -20.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TERN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.6% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.21x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TERN (7) vs ANL (1)
Institutional Metric TERN ANL Criterion Row Edge
Market Capitalization
Scale
$6.1B $677.5M Larger Scale TERN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +178.1% Higher Growth ANL
Operating Margin (TTM)
Profitability
0.0% -123.5% Higher Margin TERN
Net Profit Margin
Profitability
0.0% -124.8% Higher Margin TERN
Return on Equity (ROE)
Capital Efficiency
-14.2% -20.2% Higher ROE TERN
52-Week Range Position
Momentum
100% ($3–$53) 56% ($1–$17) Stronger Trend TERN
Beta / 30D Volatility
Risk Regime
0.07β · 2% Vol 2.61β · 79% Vol Lower Realized Risk TERN
Unified Institutional Score
Composite Signal
51.9 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite TERN
Trailing 12M Revenue (USD)
Operating Scale
$1.0M $18M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 37.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M EBITDA ($8.96 Book/Sh · -14.2% ROE) -$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANL +82.57 pp
TERN: +0.44% · ANL: +83.01%
3M Horizon ANL +17.68 pp
TERN: +43.81% · ANL: +61.49%
6M Horizon ANL +735.96 pp
TERN: +155.43% · ANL: +891.39%
1Y Horizon ANL +735.96 pp
TERN: +155.43% · ANL: +891.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TERN vs ANL. Trailing 12-month operating profitability (TERN 0.0% vs ANL -123.5%) and valuation multiples (TERN N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TERN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-14.2% · N/M
ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TERN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TERN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TERN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TERN vs ANL Key Questions & Quantitative Answers

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (51.9/100 HOLD vs. 48.3/100 HOLD) after splitting the core matrix 7–1 (led by Profitability & Quality, Options & Positioning), while ANL wins 3–2 across the 6-pillar growth and valuation breakdown. TERN trades at $52.95 (N/M Forward P/E, 0.0% operating margin) versus ANL at $9.97 (N/M Forward P/E, -123.5% operating margin). Growth vs. Quality Trade-Off: TERN earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. ANL 48.3/100 HOLD) and 0.07β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TERN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 74.7); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: TERN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with ANL at +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin). On trailing 12-month operating scale, TERN generates $1.0M in USD-normalized revenue versus $18M for ANL. In operating R&D and SG&A reinvestment, TERN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANL.

ANL screens cheaper on headline valuation multiples. TERN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TERN (-14.2% ROE) versus ANL (-20.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TERN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 2% Vol realized risk). By comparison, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.